tepotinib,osimertinib
emd serono,astrazeneca,merck
['lcsm,(-blcsm)', 'insight 2', 'serono']
 of wraps up the #esmo22 late breaking oral presentation of the phase ii insight 2 initial results. view the abstract. #lcsm #hcpsonly
Official Twitter for US Oncology business of EMD Serono a business of Merck KGaA Darmstadt, Germany. 
Intended for U.S. audience
CG: ??https://t.co/DN8q8OvEDb